Corrigendum to “The probable roles of valsartan in alleviating chronic obstructive pulmonary disease following co-exposure to cold stress and fine particulate matter” [Environ. Toxicol. Pharmacol. 60 (2018) 230–236]
Publication date: Available online 21 May 2019Source: Environmental Toxicology and PharmacologyAuthor(s): Jiangtao Liu, Lei Guo, Kai Zhang, Quanquan Song, Qiaozhen Wei, Qin Bian, Tingting Liang, Jingping Niu, Bin Luo (Source: Environmental Toxicology and Pharmacology)
Source: Environmental Toxicology and Pharmacology - May 22, 2019 Category: Environmental Health Source Type: research

Identification of potential therapeutic target genes in mouse mesangial cells associated with diabetic nephropathy using bioinformatics analysis.
In conclusion, Jun, Ptgs2, Fn1, Cdk2, Fos, Hspa5, Hsp90b1, Hyou1, RHOB, CFH and KLF15 may be potential therapeutic targets for mesangial cells associated with DN, which may provide insight into DN treatment strategies. PMID: 31105790 [PubMed] (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - May 21, 2019 Category: General Medicine Tags: Exp Ther Med Source Type: research

Valsartan chronotherapy reverts the non-dipper pattern and improves blood pressure control through mediation of circadian rhythms of the renin-angiotensin system in spontaneous hypertension rats.
CONCLUSION: VSA may be more efficacious than VWA in controlling BP, circadian BP rhythm and blood RAS rhythm. Recent cardiovascular outcome investigations substantiate that chronotherapy treatment might be a novel therapeutic strategy for hypertension therapy. ABBREVIATIONS: Angiotensin-converting enzyme (ACE); Angiotensin converting enzyme inhibitors (ACEIs); Angiotensin II (ANG II); Analysis of variance (ANOVA); Angiotensin receptor blockers (ARBs); Blood Pressure (BP); Calcium Antagonists Calcium Channel Blockers (CCB); Chronic kidney diseases (CKD); Sodium carboxyl methyl cellulose (CMC-Na); Cardiac mass index (CM...
Source: Chronobiology International - May 17, 2019 Category: Biology Authors: Yang K, Wang Y, Ding Y, Cui H, Zhou D, Chen L, Ma Z, Wang W, Zhang W, Luan J Tags: Chronobiol Int Source Type: research

Effect of sacubitril/valsartan on cardiac filling pressures in patients with heart failure: Suggestions for statistical analysis
We read with great interest the recent article entitled “Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction” by Khan et al. [1]. In this paper, authors assessed the change in hemodynamic profiles after sacubitril/valsartan treatment. They enrolled 13 subjects with heart failure with redu ced ejection fraction (HFrEF) and CardioMEMS™ device. Transmitted pulmonary artery (PA) pressures from device were averaged and compared for one week before and after initiation of sacubitril/valsartan, after dose increase and at 3-month follow-up. (Source: I...
Source: International Journal of Cardiology - May 15, 2019 Category: Cardiology Authors: Sercan Okutucu, Nurbanu Bursa Tags: Letter to the editor Source Type: research

Valsartan/hydrochlorothiazid е induced prostatе carcinoma in a patient who subsequently developed melanoma.
Valsartan/hydrochlorothiazidе induced prostatе carcinoma in a patient who subsequently developed melanoma. J Biol Regul Homeost Agents. 2019 May 13;33(4) Authors: Tchernev G, Temelkova I PMID: 31079442 [PubMed - as supplied by publisher] (Source: Journal of Biological Regulators and Homeostatic Agents)
Source: Journal of Biological Regulators and Homeostatic Agents - May 15, 2019 Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research

Different effects of norepinephrine and nerve growth factor on atrial fibrillation vulnerability.
Abstract BACKGROUND: The sympathetic nerve plays an important role in atrial fibrillation (AF) vulnerability. Norepinephrine (NE) has a relationship with AF and nerve growth factor (NGF) injection can induce sympathetic innervation. However, the mechanisms of NE and NGF on AF vulnerability remain unclear. METHODS: Four groups of rabbits were studied: the control group, the NGF group, the NE group, and the NGF+valsartan+metoprolol group. After receiving drugs for 15 days, induced AF was observed, and left atrium (LA) tissues were obtained. Immunocytochemical staining of cardiac nerves and ionic remodeling were...
Source: Journal of Cardiology - May 15, 2019 Category: Cardiology Authors: Yang M, Zhang S, Liang J, Tang Y, Wang X, Huang C, Zhao Q Tags: J Cardiol Source Type: research

A per ‐protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region
ConclusionsInitiating sacubitril/valsartan through a defined protocol selects for appropriate candidates and guides starting dose and titration. Overall, significant success can be achieved in replacing ACEI or ARB by sacubitril/valsartan in symptomatic heart failure with reduced ejection fraction patients. (Source: ESC Heart Failure)
Source: ESC Heart Failure - May 14, 2019 Category: Cardiology Authors: Bassam Atallah, Ziad G. Sadik, Mohamed Hisham, Oussama Kalagieh, Iman Hamour, Guirgis Gabra, Mosaad El Banna, Medhat Soliman, Antoine Cherfan, Feras Bader Tags: Original Research Article Source Type: research

Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standards of Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
Abstract PURPOSE: Sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is a possible treatment option for chronic heart failure patients with reduced ejection fraction (HFrEF). The aim of this study was to estimate the cost-effectiveness of sacubitril/valsartan use in South Korea for treating patients with HFrEF compared with that of enalapril, an angiotensin-converting enzyme inhibitor, and with angiotensin receptor blockers (ARBs). METHODS: A Markov model was designed to estimate the lifetime cost-effectiveness of treatment for patients with HFrEF. Cohorts in the alive-...
Source: Clinical Therapeutics - May 14, 2019 Category: Drugs & Pharmacology Authors: Park SK, Hong SH, Kim H, Kim S, Lee EK Tags: Clin Ther Source Type: research

The contamination of valsartan and other sartans, part 1: New findings
Publication date: Available online 11 May 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Fritz Sörgel, Martina Kinzig, Mona Abdel-Tawab, Clemens Bidmon, André Schreiber, Steffen Ermel, Jonas Wohlfart, Axel Besa, Oliver Scherf-Clavel, Ulrike HolzgrabeAbstractIn July 2018 one of the bestselling antihypertensive agents valsartan manufactured in China was found to be contaminated by the “probably carcinogenic” nitrosamine N-nitrosodimethylamine (NDMA), followed by the detection of N-nitrosodiethylamine (NDEA) by us and others soon after. Our work also revealed that two additiona...
Source: Journal of Pharmaceutical and Biomedical Analysis - May 12, 2019 Category: Drugs & Pharmacology Source Type: research

Potential Drug Interactions in Critically Ill Patients: Sacubitril/Valsartan and Mexiletine
Cardiology 2019;142:81 –82 (Source: Cardiology)
Source: Cardiology - May 10, 2019 Category: Cardiology Source Type: research

Sacubitril/valsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men.
CONCLUSIONS: Sacubitril/valsartan combined with a DPP-4 inhibitor lead to markedly higher concentrations of intact GLP-1 than DPP-4 inhibition alone, supporting a role for both neprilysin and DPP-4 in the metabolism of GLP-1 in humans, a finding which may have therapeutic implications. PMID: 31074791 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - May 10, 2019 Category: Endocrinology Authors: Wewer Albrechtsen NJ, Mark PD, Terzic D, Hansen LH, Andersen UØ, Hartmann B, Carr RD, Gustafsson F, Deacon CF, Holst JJ, Goetze JP, Plomgaard P Tags: J Clin Endocrinol Metab Source Type: research

Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF
ConclusionsJust under half of patients in this global trial had nonischemic HF with reduced ejection fraction, with idiopathic and hypertensive the most commonly ascribed etiologies. Adjusted outcomes were similar across etiologic categories, as was the benefit of sacubitril/valsartan over enalapril. (Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure; NCT01035255)Central Illustration (Source: JACC: Heart Failure)
Source: JACC: Heart Failure - May 9, 2019 Category: Cardiology Source Type: research

Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials
ConclusionThis article presents key clinical trials completed during 2018 and should be valuable to both cardiology clinicians and researchers. (Source: Advances in Therapy)
Source: Advances in Therapy - May 7, 2019 Category: Drugs & Pharmacology Source Type: research

Effects of Low-Dose Sacubitril/Valsartan on Different Stages of Cardiac Hypertrophy in Salt-Loaded Hypertensive Rats
Conclusions: Low-dose sacubitril/valsartan may have different effects depending on the stage of cardiac hypertrophy in rats. (Source: Journal of Cardiovascular Pharmacology)
Source: Journal of Cardiovascular Pharmacology - May 1, 2019 Category: Cardiology Tags: Original Article Source Type: research

Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure
Conclusion: In patients with HF and reduced EF, where GDMT is appropriately achieved, indication to sacubitril/valsartan treatment is around 38%. (Source: Journal of Cardiovascular Pharmacology)
Source: Journal of Cardiovascular Pharmacology - May 1, 2019 Category: Cardiology Tags: Original Article Source Type: research

Additional 4 cases of valsartan/irbesartan-induced melanomas?
Authors: Tchernev G, Temelkova I PMID: 31032596 [PubMed - as supplied by publisher] (Source: Journal of Biological Regulators and Homeostatic Agents)
Source: Journal of Biological Regulators and Homeostatic Agents - April 30, 2019 Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research

Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view.
Authors: Quiroga B, de Santos A, Sapiencia D, Saharaui Y, Álvarez-Chiva V Abstract BACKGROUND AND OBJECTIVES: Sacubitril/valsartan reduces cardiovascular morbidity and mortality in patients with systolic dysfunction. The aim of the present study was to assess the evolution of chronic kidney disease (CKD) patients after initiating sacubitril/valsartan. MATERIAL AND METHODS: We included 66 consecutive CKD patients with systolic dysfunction followed up in outpatient care. Patients had to meet the inclusion criteria of having a New York Heart Association class ii to iv, receiving maximum tolerated doses of o...
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - April 29, 2019 Category: Urology & Nephrology Tags: Nefrologia Source Type: research

Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan
Conclusions: SV in women with HFrEF has a similar tolerability as in men. Females seem to have a more frequent functional class improvement than males.Cardiology 2019;142:73 –78 (Source: Cardiology)
Source: Cardiology - April 18, 2019 Category: Cardiology Source Type: research

The contamination of valsartan and other sartans, Part 2: Untargeted Screening reveals contamination with amides additionally to known nitrosamine impurities
Publication date: Available online 16 April 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Oliver Scherf-Clavel, Martina Kinzig, Axel Besa, André Schreiber, Clemens Bidmon, Mona Abdel-Tawab, Jonas Wohlfart, Fritz Sörgel, Ulrike HolzgrabeAbstractThe recent incidences of contaminated valsartan drug products gave rise to review the suitability of current impurity profiling workflows implemented at authorities and pharmaceutical companies. The major drawback of targeted impurity profiling, where a considerable amount of prior knowledge about possible contaminants is necessary, is the fact t...
Source: Journal of Pharmaceutical and Biomedical Analysis - April 17, 2019 Category: Drugs & Pharmacology Source Type: research

Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Abstract The presence of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurities in angiotensin II receptor blocker (ARB) drugs containing tetrazole ring has triggered worldwide product recalls. The purpose of this article is to identify the potential gap area in current pharmaceutical industry practice that might have led to the NMDA and NDEA impurities escaping the drug manufacturer's and FDA's attention. The impact of process change was not adequately assessed by the manufacturer of contaminated APIs (active pharmaceutical ingredients), and potential for generation of mutagenic or other toxic ...
Source: AAPS PharmSciTech - April 15, 2019 Category: Drugs & Pharmacology Authors: Charoo NA, Ali AA, Buha SK, Rahman Z Tags: AAPS PharmSciTech Source Type: research

Endothelial progenitor cells, rosuvastatin and valsartan have a comparable effect on repair of balloon-denudated carotid artery injury.
This study tested the therapeutic role of autologous endothelial progenitor cells (EPCs)/rosuvastatin-(Rosu)/valsartan-(Val) on repair of injured carotid ECs. Male Sprague-Dawley rats (n = 60) were categorized into five groups [sham-control (SC), left common carotid artery injury induced by balloon denudation (LCABD), LCABD + Rosu (10 mg/kg/day), LCABD + Val (20 mg/kg/day), and LCABD + EPC (1.2 × 106)]. By day 5, the LCA was harvested from each rat (n = 6/each time interval in group) after the procedure. Carotid-ring angiogenesis was significantly lower in LCABD than the other groups (all P
Source: American Journal of Translational Research - April 13, 2019 Category: Research Tags: Am J Transl Res Source Type: research

Real ‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany
ConclusionsMost patients prescribed sac/val are not initiated on the recommended dose nor up ‐titrated as recommended by the EU Summary of Product Characteristics. Initiation of sac/val was associated with high persistence and compliance and a dose reduction of diuretics. Barriers to up‐titration must be explored. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 11, 2019 Category: Cardiology Authors: Rolf Wachter, Ana F. Fonseca, Bogdan Balas, Elisabeth Kap, Johanna Engelhard, Raymond Schlienger, Sven Klebs, Sara Bruce Wirta, Karel Kostev Tags: Research Article Source Type: research

Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
CONCLUSIONS: Our study demonstrated the effectiveness of sacubitril/valsartan on HFrEF patients in real world practice, including those with advanced renal impairment. PMID: 30982680 [PubMed - as supplied by publisher] (Source: Journal of Cardiology)
Source: Journal of Cardiology - April 11, 2019 Category: Cardiology Authors: Chang HY, Feng AN, Fong MC, Hsueh CW, Lai WT, Huang KC, Chong E, Chen CN, Chang HC, Yin WH Tags: J Cardiol Source Type: research

Angiotensin blockade attenuates diabetic nephropathy in hypogonadal adult male rats.
This study examined the effect of the aromatase inhibitor letrozole (0.5 mg/kg) alone or in combination with the angiotensin-receptor blocker valsartan (30 mg/kg) against streptozocin-induced diabetic nephropathy (DN) in hypogonadal (HG) rats for 12 weeks. First, we tested the HG effect on hormone levels, inflammatory cytokines, and oxidative stress in non-diabetic (ND) and diabetic (D) rats. HG was induced with the luteinizing hormone-releasing hormone antagonist cetrorelix (0.71 mg/kg). Diabetes enhanced hormonal hypogonadism and increased inflammation and oxidative stress. Next, experiments examined the effect of early ...
Source: Canadian Journal of Physiology and Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Authors: Makary S, Abdo M, Hassan WA, Tawfik MK Tags: Can J Physiol Pharmacol Source Type: research

Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.
PMID: 30955360 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - April 8, 2019 Category: Cardiology Authors: Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E Tags: Circulation Source Type: research

IJERPH, Vol. 16, Pages 1196: Simultaneous Determination of Moxifloxacin and Flavoxate by RP-HPLC and Ecofriendly Derivative Spectrophotometry Methods in Formulations
oname Simple, fast, and precise reversed-phase (RP)-high-performance liquid chromatography (HPLC) and two ecofriendly spectrophotometric methods were established and validated for the simultaneous determination of moxifloxacin HCl (MOX) and flavoxate HCl (FLX) in formulations. Chromatographic methods involve the separation of two analytes using an Agilent Zorbax SB C18 HPLC column (150 mm × 4.6 mm; 5 µm) and a mobile phase consisting of phosphate buffer (50 mM; pH 5): methanol: acetonitrile in a proportion of 50:20:30 v/v, respectively. Valsartan was used as an internal standard. Analytes we...
Source: International Journal of Environmental Research and Public Health - April 3, 2019 Category: Environmental Health Authors: Mahesh Attimarad Muhammad Shahzad Chohan Abdulmalek Ahmed Balgoname Tags: Article Source Type: research

Analysis and fate of 14 relevant wastewater-derived organic pollutants in long-term exposed soil.
D, Pérez S Abstract The growing use of reclaimed water in agriculture worldwide calls for developing high-sensitivity methods to quantify wastewater-derived organic contaminants in soils so that the potential risk of this irrigation practice can be properly assessed. This work describes an analytical method for the determination of trace levels of 14 drugs that are known to be poorly removed during conventional wastewater treatment in soil. The analytes selected for investigation included ten pharmaceuticals from different therapeutic classes (carbamazepine, diclofenac, cis-diltiazem, lamotrigine, methadone...
Source: Analytical and Bioanalytical Chemistry - April 1, 2019 Category: Chemistry Authors: Montemurro N, Postigo C, Chirón S, Barcelò D, Pérez S Tags: Anal Bioanal Chem Source Type: research

Vasodilatory Properties of Sacubitril/Valsartan Explored in Hypertensives Aged Over 55  Years: A Meta-Analysis
AbstractIntroductionA complete assessment of the efficacy and safety of sacubitril/valsartan for hypertension is not available yet.MethodsTherefore, we performed a meta-analysis of randomized controlled trials (RCTs) by incorporating only RCTs including patients aged> 55 years in which the antihypertensive efficacy and safety of sacubitril/valsartan were compared with those of a reference drug (comparator). The mean reductions in systolic blood pressure and diastolic blood pressure in the sitting position (msSBP and msDBP, respectively)were assumed as primary efficacy endpoints. Even mean reduction in ambulatory systoli...
Source: High Blood Pressure and Cardiovascular Prevention - April 1, 2019 Category: Cardiology Source Type: research

Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective
The cost-effectiveness, from the Australian health care perspective, of switching patients with heart failure and reduced ejection fraction (HFREF) stable on angiotensin converting enzyme (ACE) inhibitors / angiotensin II receptor blockers (ARBs) to sacubitril/valsartan is unclear. We sought to assess the cost-effectiveness of sacubitril/valsartan versus enalapril in patients with HFREF in the contemporary Australian setting. (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - March 28, 2019 Category: Cardiology Authors: Ken Lee Chin, Ella Zomer, Bing H. Wang, Danny Liew Tags: Original Article Source Type: research

Kimura's disease with membranoproliferative glomerulonephritis: a case report with literature review.
Authors: Su S, Chen X, Li J, Yu J, Zhang L Abstract BACKGROUND: Kimura's disease is a rare disease and its etiology is still unclear. Here we reported a case with lymphadenopathy complicated with secondary membranoproliferative glomerulonephritis. CASE PRESENTATION: A 46-year-old Chinese man presented with bilateral tumor-like nodules over his neck during the past 6 months and developed edema for 15 days. His blood pressure was 145/90 mmHg, multiple 1 × 1 cm masses were found over bilateral post-auricular and submandibular areas, along with trace edema of the lowe...
Source: Renal Failure - March 27, 2019 Category: Urology & Nephrology Tags: Ren Fail Source Type: research

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
Diabetic nephropathy (DN) is characterized by glomerular and tubulointerstitial injury, proteinuria and remodeling. Here we examined whether the combination of an inhibitor of neprilysin (sacubitril), a natriu... (Source: Cardiovascular Diabetology)
Source: Cardiovascular Diabetology - March 25, 2019 Category: Cardiology Authors: Javad Habibi, Annayya R. Aroor, Nitin A. Das, Camila M. Manrique-Acevedo, Megan S. Johnson, Melvin R. Hayden, Ravi Nistala, Charles Wiedmeyer, Bysani Chandrasekar and Vincent G. DeMarco Tags: Original investigation Source Type: research

Antihypertensive effect of sacubitril/valsartan: a meta-analysis.
Authors: De Vecchis R, Ariano C, Soreca S Abstract INTRODUCTION: Sacubitril/valsartan used as an antihypertensive agent has not yet been completely assessed as regards its efficacy and safety. Thus, to investigate them in elderly hypertensive patients, a meta-analysis has been performed. EVIDENCE ACQUISITION: The meta-analysis incorporated only randomized controlled trials(RCTs) in which sacubitril/valsartan was compared with a reference drug. The mean reductions in systolic blood pressure( msSBP) and diastolic blood pressure( msDBP) in the sitting position as well as the mean reductions in ambulatory systolic ...
Source: Minerva Cardioangiologica - March 23, 2019 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Case of a patient with heart failure, dilated cardiomyopathy, and atrial fibrillation treated with sacubitril/valsartan.
We report a case of a 29-year old male with HF, dilated cardiomyopathy possibly related to myocarditis, and atrial fibrillation with reduced ejection fraction. Sacubitril/valsartan treatment was initiated after two years of standard treatment. In two years, therapy with sacubitril/valsartan led to persistence in sinus rhythm and progressive recovery of ejection fraction, functionality, and reduction of cardiac volumes. The patient is currently in good condition and has suspended diuretic therapy in the last six months. PMID: 30895821 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 23, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35.
We reported a case series of ten patients with stable chronic HF and LVEF ≤35% (mean age: 64 ± 8 years; 30% female), referred to our outpatient HF clinic, treated with sacubitril/valsartan, in whom the global amelioration of NYHA class and LVEF coupled a clinically significant decrease in BNP levels and a reduction of loop diuretic dose. Average sacubitril/valsartan daily dose was 220 mg. The median duration of treatment was fifteen months (range: 6-21 months). Seventy per cent of patients exhibited an improvement in the exercise tolerance, as indicated by the change in NYHA class. There was ...
Source: Current Medical Research and Opinion - March 23, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Management of patient with heart failure: Italian "field practice" experience on sacubitril/valsartan.
Management of patient with heart failure: Italian "field practice" experience on sacubitril/valsartan. Curr Med Res Opin. 2019 Mar 21;:1 Authors: De Angelis G PMID: 30894037 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 23, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Sacubitril/valsartan effect on left ventricular remodeling: the case of a super-responder.
In conclusion, our case showed a strong beneficial effect of Sacubitril/Valsartan on reverse remodeling and LVEF beyond the benefits of concomitant optimal medical therapy. This result is particular noteworthy because it was obtained although patient wasn't able to reach the full dose of the drug. Physician should always consider this drug effect when more demanding therapeutic strategies are needed for their HF patients. PMID: 30894032 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 23, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Sacubitril/valsartan treatment improved the clinical outcome and reduced the hospitalization rate in three patients with chronic heart failure: a case series.
Authors: Severini D, Mboumi K Abstract Sacubitril/valsartan was shown to be effective in improving the clinical outcome and reducing hospitalization rate and mortality in patients with heart failure (HF) and reduced left ventricular ejection fraction (HFrEF). Here we report a case series of three patients with HFrEF associated with mitral insufficiency (case #1), dilated cardiomyopathy (case #2), and chronic ischaemia (case #3). The first case was a 49-year-old male and the further two were 70-year-old male patients. After previous ineffective treatment, the administration of sacubitril/valsartan led to a rapid and...
Source: Current Medical Research and Opinion - March 23, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
ConclusionsBetween 34 and 76% of symptomatic patients with HF-REF in a ‘real world’ population are eligible for treatment with sacubitril/valsartan, depending on background ACEI/ARB dose. The most common reason for ineligibility is a low natriuretic peptide level. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 23, 2019 Category: Cardiology Source Type: research

Is the cardioprotective effect of LCZ696 linked to increased cardiac regeneration?
Publication date: April 2019Source: Archives of Cardiovascular Diseases Supplements, Volume 11, Issue 2Author(s): A. Carboni, C. Bielmann, S. Rignault-Clerc, N. Rosenblatt-VelinLCZ696 treatment reduces the mortality and the risk of hospitalization of patients with hypertension or heart failure with a preserved ejection fraction by 20%. The LCZ696 molecule associates both an angiotensin receptor blocker (valsartan) and an inhibitor of neprilysin (NEP, sacubitril). NEP is an endopeptidase able to degrade several factors such as the natriuretic peptides, angiotensin II, bradykinin, endothelin-1.Despite the cardioprotective ef...
Source: Archives of Cardiovascular Diseases Supplements - March 22, 2019 Category: Cardiology Source Type: research

Validation of a preclinical model of heart failure with reduced ejection fraction by a dual angiotensin receptor-neprilysin inhibitor and an angiotensin-converting enzyme inhibitor
ConclusionsIn summary, the SHR PMI model has a good predictive value and can be used as preclinical model for the evaluation of new therapeutic strategy in HFrEF [1], [2]. (Source: Archives of Cardiovascular Diseases Supplements)
Source: Archives of Cardiovascular Diseases Supplements - March 22, 2019 Category: Cardiology Source Type: research

Improvement of diastolic function in patients with heart failure and reduced ejection fraction treated by sacubitril/valsartan
Publication date: April 2019Source: Archives of Cardiovascular Diseases Supplements, Volume 11, Issue 2Author(s): M. Godet, O. Raitière, H. Chopra, C. Fauvel, P. Guignant, M. Penso, H. Eltchaninoff, F. BauerBackgroundPatients with heart failure and reduced ejection fraction (HF rEF) have a poor prognosis, even worse when diastolic dysfunction progresses.PurposeThe purpose of our work was to evaluate the reversibility of diastolic dysfunction after sacubitril/valsartan administration in patients with HF REF.MethodsA total of 65 patients in NYHA functional class 2–3 and treated by ACE inhibitor or AAR2, were pro...
Source: Archives of Cardiovascular Diseases Supplements - March 22, 2019 Category: Cardiology Source Type: research

Efficacy and tolerance evaluation of an ambulatory use of sacubitril/valsartan among patients with heart failure due to reduced ejection fraction
Publication date: April 2019Source: Archives of Cardiovascular Diseases Supplements, Volume 11, Issue 2Author(s): C. Chong-Nguyen, M. Jullien, M. Lescroart, C. Morgat, T. Rolland, Y. Temmar, N. GhanemIntroductionHeart failure due to reduced ejection fraction (HFrEF) has a real functional impact in daily life for patients. Improving the quality of life is one of the main goals when treating HF. The study PARADIGM-HF showed a 20% reduction of mortality and hospitalization for patients treated with sacubitril/valsartan (LCZ696).ObjectiveThe aim of our study was to evaluate patients with HFrEF after an ambulatory introducing o...
Source: Archives of Cardiovascular Diseases Supplements - March 22, 2019 Category: Cardiology Source Type: research

CHINA STudy of valsartan/amlodipine fixed-dose combination-bAsed long-Term blood pressUre management in HypertenSive patients: A one-year registry (CHINA STATUS III).
Authors: Huo Y, Gu Y, Ma G, Guo J, Xiong L, Luo Z, Xie J, Li W, Zhao J, Yan X, Liu W, Xu Y, Bao X, Zhao L, Yang M, Wang B Abstract OBJECTIVE: The present observational study evaluated long-term management of hypertension in patients who received treatment with valsartan and amlodipine in a single-pill combination (Val/Aml SPC) in a real-world setting in China (Chinese Clinical Trial Registry number ChiCTR1900021324). METHODS: This was a prospective, observational, multicenter, real-world registry study wherein patients with hypertension who had already received Val/Aml SPC (80/5 mg) for at least 4 weeks ...
Source: Current Medical Research and Opinion - March 20, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Real-world prevalence of adverse events after initiating sacubitril/valsartan compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure
Sacubitril/valsartan is a novel medication that acts as a neprilysin and angiotensin receptor blocker.1 Its overwhelming benefit seen in its main clinical trial, PARADIGM-HF, led to its incorporation into the American College of Cardiology(ACC)/American Heart Association(AHA)/Heart Failure Society of America (HFSA) guidelines.2-4 In the PARADIGM-HF trial, sacubitril/valsartan demonstrated a reduction in the composite endpoint of cardiovascular death or hospitalization for worsening heart failure when compared to enalapril. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 20, 2019 Category: Cardiology Authors: Sarah Adie, Abbas Bitar, Sarah Hanigan, Kristen Pogue, Todd Koelling, Michael Dorsch Tags: Research Letter Source Type: research

Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure
Sacubitril/valsartan is a novel medication that acts as a neprilysin and angiotensin receptor blocker.1 Its overwhelming benefit as seen in its main clinical trial, PARADIGM-HF, led to its incorporation into the American College of Cardiology/American Heart Association/Heart Failure Society of America guidelines.2 –4 In the PARADIGM-HF trial, sacubitril/valsartan demonstrated a reduction in the composite end point of cardiovascular death or hospitalization for worsening heart failure compared with enalapril. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 20, 2019 Category: Cardiology Authors: Sarah Adie, Abbas Bitar, Sarah Hanigan, Kristen Pogue, Todd Koelling, Michael Dorsch Tags: Research Letter Source Type: research

Incidence of Vasoplegic Syndrome after Cardiac Transplant in Patients Treated with Sacubitril/Valsartan
Vasoplegic syndrome (VS) is associated with high morbidity and mortality after heart transplant (HT). ACE-inhibitors have shown to increase the risk of VS after heart surgery, but little is known about the effect of Sacubitril/Valsartan (SAC/ VALS), a more potent vasodilator used in heart failure. Profound vasoplegia was reported after HT in a patient receiving SAC/VALS. We aim to assess whether SAC/VALS is associated with a higher incidence of VS in patients undergoing a HT. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: J.M. Dominguez, J. P àmies, S. Mirabet, E. García-Romero, J. Gonzalez-Costello, M. Farrero, F. Perez-Villa Tags: 680 Source Type: research

Sacubitril/valsartan can improve exercise performance in systolic chronic heart failure patients: a case report.
CONCLUSIONS: We present a case of a systolic HF patient successfully treated with sacubitril/valsartan who showed a rapid improvement of exercise performance at CPET. PMID: 30864901 [PubMed - in process] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 14, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
CONCLUSIONS: Based on our real-life experience, in HFrEF patients with NYHA class II-III, the new angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril/valsartan was effective in improving HF management, both from the clinical and the echocardiographic perspective. PMID: 30864900 [PubMed - in process] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 14, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Management of a patient with heart failure by sacubitril/valsartan: improvement of functional capacity.
We report a case of a 48 year old male with HF with reduced ejection fraction (HFrEF) due to hypertensive cardiomyopathy (New York Heart Association [NYHA] class III). Therapy with sacubitril/valsartan was initiated after some years of other treatments, which did not lead to any positive outcome in HF, quality of life and clinical functions. After only 1 month of sacubitril/valsartan therapy, the patient reported a significant improvement in quality of life, and in 6 months his NYHA class switched from III to I. PMID: 30864899 [PubMed - in process] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 14, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research